Busca avançada
Ano de início
Entree
(Referência obtida automaticamente do Web of Science, por meio da informação sobre o financiamento pela FAPESP e o número do processo correspondente, incluída na publicação pelos autores.)

Cannabidiol for Rapid Eye Movement Sleep Behavior Disorder

Texto completo
Autor(es):
de Almeida, Carlos M. O. [1] ; Brito, Manuelina M. C. [2] ; Bosaipo, Nayanne B. [2] ; Pimentel, Angela V. [2] ; Tumas, Vitor [2] ; Zuardi, Antonio W. [2, 3] ; Crippa, Jose A. S. [2, 3] ; Hallak, Jaime E. C. [2, 3] ; Eckeli, Alan L. [2]
Número total de Autores: 9
Afiliação do(s) autor(es):
[1] State Univ Amazonas, Sch Hlth Sci, Manaus, Amazonas - Brazil
[2] Univ Sao Paulo, Fac Med Ribeirao Preto, Div Neurol, Dept Neurosci & Sci Behav, Sao Paulo - Brazil
[3] CNPq FAPESP CAPES, Natl Inst Sci & Technol Translat Med, Sao Paulo - Brazil
Número total de Afiliações: 3
Tipo de documento: Artigo Científico
Fonte: MOVEMENT DISORDERS; v. 36, n. 7, p. 1711-1715, JUL 2021.
Citações Web of Science: 0
Resumo

Background REM sleep behaviour disorder (RBD) is a common non-motor feature of Parkinson's disease (PD). Cannabidiol (CBD) is one of the main non-psychoactive components of Cannabis sativa and may represent an alternative route for treating RBD. Objective This study assessed the efficacy and safety of CBD for RBD in PD. Methods We conducted a phase II/III, double-blind, placebo-controlled clinical trial in 33 patients with RBD and PD. Patients were randomized 1:1 to CBD in doses of 75 to 300mg or matched capsules placebo and were followed up for 14 weeks. The primary outcomes were the frequency of nights with RBD, CGI-I, and CGI-S. Results CBD showed no difference to placebo for primary outcomes. Regarding secondary outcomes, we observed a significant improvement in average sleep satisfaction from the 4th to 8th week in the CBD versus placebo group with P = 0.049 and P = 0.038, respectively. Conclusion CBD, as an adjunct therapy, showed no reduction in RBD manifestations in PD patients. A transient improvement in sleep satisfaction with a dose of 300mg has been noted. (c) 2021 International Parkinson and Movement Disorder Society (AU)

Processo FAPESP: 08/09009-2 - Uso crônico de crack: densidade de transportador de dopamina, fatores genéticos e funcionamento executivo
Beneficiário:Acioly Luiz Tavares de Lacerda
Modalidade de apoio: Auxílio à Pesquisa - Regular